Trial Profile
A Pragmatic randomized study to evaluate the comparative effectiveness of Akynzeo® and Standard of care (including Emend®) for the prevention of nausea and vomiting (CINV) in cancer patients receiving moderately emetogenic chemotherapy in France
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2020
Price :
$35
*
At a glance
- Drugs Netupitant/palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Sponsors Vifor
- 07 Sep 2020 Status changed from recruiting to completed.
- 28 Sep 2018 New trial record